INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center

Stock News

Sep 12

INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1139178921"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139178921\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139178921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139178921","market":"sg","top_or_hot":-1,"title":"INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center","media":"Stock News","content":"<p>INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Issues First Prescription for Core Type 2 Diabetes Treatment Product in Macau at HuaBao Medical Center\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-12 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药－Ｂ","start_time":0,"source_url":"","article_id":"1139178921","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139178921","pubTimestamp":1757682617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","02591":"银诺医药－Ｂ","BK1161":"生物科技"},"translate_title":"英诺健-B(02591)在华宝医疗中心开出澳门核心2型糖尿病治疗产品首张处方","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"02591":1},"content_text":"INNOGEN-B (02591) announced that the company has been actively advancing the global expansion of its core product (isupaglutide alpha) and received BLA (Biologics License Application) approval for its core product to treat type 2 diabetes (T2D) in the Macao Special Administrative Region of the People's Republic of China (Macau) in June 2025. The company's board of directors is pleased to announce that on September 12, 2025, the first prescription for the company's core product for treating type 2 diabetes in Macau was issued at Macau HuaBao Medical Center, marking the official entry of the core product into the commercial sales stage in Macau.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}